Biotech Sage Therapeutics skyrockets more than 60% after depression drug breakthrough

Sixty-four percent of patients achieved major depressive disorder remission using SAGE-217 in the 15th day of treatment, Sage Therapeutics said.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.